KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Travere Therapeutics (TVTX) over the last 12 years, with Q3 2025 value amounting to $44.2 million.

  • Travere Therapeutics' Change in Receivables rose 594035.57% to $44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.6 million, marking a year-over-year increase of 38076.92%. This contributed to the annual value of $6.0 million for FY2024, which is 4672.41% down from last year.
  • According to the latest figures from Q3 2025, Travere Therapeutics' Change in Receivables is $44.2 million, which was up 594035.57% from $4.3 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Change in Receivables ranged from a high of $44.2 million in Q3 2025 and a low of -$5.7 million during Q3 2022
  • Its 5-year average for Change in Receivables is $3.8 million, with a median of $1.7 million in 2021.
  • As far as peak fluctuations go, Travere Therapeutics' Change in Receivables plummeted by 477377.05% in 2021, and later surged by 594035.57% in 2025.
  • Travere Therapeutics' Change in Receivables (Quarter) stood at $1.7 million in 2021, then soared by 248.26% to $6.0 million in 2022, then surged by 32.73% to $8.0 million in 2023, then plummeted by 75.1% to $2.0 million in 2024, then skyrocketed by 2125.55% to $44.2 million in 2025.
  • Its Change in Receivables was $44.2 million in Q3 2025, compared to $4.3 million in Q2 2025 and $7.2 million in Q1 2025.